Literature DB >> 26287857

Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report.

Julie E Ledgerwood, Nancy J Sullivan, Barney S Graham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26287857     DOI： 10.1056/NEJMc1505499

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Insights from clinical research completed during the west Africa Ebola virus disease epidemic.

Authors:  Amanda Rojek; Peter Horby; Jake Dunning
Journal:  Lancet Infect Dis       Date:  2017-04-28       Impact factor: 25.071

Review 2.  Single-cycle adenovirus vectors in the current vaccine landscape.

Authors:  Michael Barry
Journal:  Expert Rev Vaccines       Date:  2018-01-18       Impact factor: 5.217

Review 3.  Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.

Authors:  John J Suschak; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452

Review 4.  Immunobiology of Ebola and Lassa virus infections.

Authors:  Joseph B Prescott; Andrea Marzi; David Safronetz; Shelly J Robertson; Heinz Feldmann; Sonja M Best
Journal:  Nat Rev Immunol       Date:  2017-01-23       Impact factor: 53.106

5.  Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.

Authors:  Camilla Patrizia Hrycak; Sonja Windmann; Wibke Bayer
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

6.  Profiling the Targets of Protective CD8+ T Cell Responses to Infection.

Authors:  Joseph T Bruder; Ping Chen; Greg Ekberg; Emily C Smith; Christopher A Lazarski; Bennett A Myers; Jessica Bolton; Martha Sedegah; Eileen Villasante; Thomas L Richie; C Richter King; Joao C Aguiar; Denise L Doolan; Douglas E Brough
Journal:  Mol Ther Methods Clin Dev       Date:  2017-08-18       Impact factor: 6.698

7.  Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.

Authors:  I V Dolzhikova; O V Zubkova; A I Tukhvatulin; A S Dzharullaeva; N M Tukhvatulina; D V Shcheblyakov; M M Shmarov; E A Tokarskaya; Y V Simakova; D A Egorova; D N Scherbinin; I L Tutykhina; A A Lysenko; A V Kostarnoy; P G Gancheva; T A Ozharovskaya; B V Belugin; L V Kolobukhina; V B Pantyukhov; S I Syromyatnikova; I V Shatokhina; T V Sizikova; I G Rumyantseva; A F Andrus; N V Boyarskaya; A N Voytyuk; V F Babira; S V Volchikhina; D A Kutaev; A N Bel'skih; K V Zhdanov; S M Zakharenko; S V Borisevich; D Y Logunov; B S Naroditsky; A L Gintsburg
Journal:  Hum Vaccin Immunother       Date:  2017-02-02       Impact factor: 3.452

8.  A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks.

Authors:  Georgi Shukarev; Benoit Callendret; Kerstin Luhn; Macaya Douoguih
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.